Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,087.82
    +3,039.23 (+6.46%)
     

  • CMC Crypto 200

    1,360.04
    +83.07 (+6.51%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

PanGenomic Health Inc - PanGenomic Health Announces Q3 Financial Results

PR Newswire
·1-min read

30 November 2023

PanGenomic Health Inc.

("PanGenomic" or the "Company")

PanGenomic Health Announces Q3 Financial Results

Vancouver, British Columbia, Canada, 30 November 2023 - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has filed its unaudited financial results for the third quarterly period ending 30 September 2023 of the Company's 2023 fiscal year. The full set of Consolidated Financial Statements and Management Discussion and Analysis can be viewed by visiting the Company's website at www.pangenomic.com or its profile page on SEDAR at www.sedar.com.

ADVERTISEMENT

The Directors of PanGenomic take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For more information, please contact:

Jerry Lai, Investor Relations Maryam Marissen, President & CEO

PanGenomic Health Inc. PanGenomic Health Inc.

778 743 4642 778 743 4642

ir@pangenomic.com info@pangenomic.com

Novum Securities Limited, AQSE Corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalised, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.